PML/RARA gene fusion probe, PML/RARA (CE-IVD)
Catalog No : FP-005
513.00€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | PML/RARA gene fusion probe, PML/RARA (CE-IVD) | ||
|---|---|---|---|
| Catalog No | FP-005 | ||
| Supplier’s Catalog No | FP-005 | ||
| Supplier | Wuhan Healthcare Biotech | ||
| Source antigen | PML | ||
| Reactivity | PML | ||
| Cross reactivity | None | ||
| Applications | Fluorescence In Situ Hybridization (FISH) | ||
| Molecular weight | N/A | ||
| Storage | -20°C | ||
|---|---|---|---|
| Other names | |||
| Grade | Molecular diagnostic grade | ||
| Purity | N/A | ||
| Form | Liquid | ||
| Reactivity life | 12 months when stored properly according to instructions | ||
| Note | For Professional In Vitro diagnostics | ||
| Description | PML/RARA fusion gene is a characteristic marker of acute promyelocytic leukemia (APL). PML / RARA fusion proteins inhibit the differentiation and maturation of promyelocytes through dominant negative inhibition, thereby blocking cell differentiation and leading to sustained proliferation. All trans retinoic acid (ATRA) and arsenic trioxide can degrade PML/RARA fusion protein, restore the function of wild type PML and RARA gene, relieve the inhibition of gene transcription, induce cell differentiation and apoptosis, so that APL can be effectively treated. The combined use of ATRA and chemotherapy can achieve a complete remission rate of APL for 90%~95%, More than 70% of the patients can survive for a long time. | ||
Product Details
© 2020 Imugex All Rights Reserved